Abstract
Cancer stem cells (CSCs) are a subset of cells within tumours that have the ability to selfrenew, differentiate and resist both chemotherapy and radiotherapy. Evidence has emerged in recent years to support liver cancer stem cells (LCSCs) as the key tumour initiating cells and major drivers of tumour progression in hepatocellular carcinoma (HCC). Currently the major approaches to targeting LCSCs are ablating the expression of LCSC markers, disruption of key LCSCs signaling pathways, micro-RNA or siRNA targeting, inducing differentiation of LCSCs and the disruption of chemoresistance of LCSCs. However, complex crosstalk amongst gene regulatory pathways in LCSCs provides a major barrier in implementing these approaches in a clinical setting. Given these findings a deeper understanding of the pathways that mediate LCSC tumourigenesis is imperative for developing new therapeutic strategies for HCC and to improve clinical outcomes.
Keywords: Chemoresistance, differentiation, hepatocellular carcinoma, liver cancer stem cells, micro-RNA, self-renewal, signaling pathways.
Current Gene Therapy
Title:Targeting Cancer Stem Cells as a Therapeutic Approach in Liver Cancer
Volume: 15 Issue: 2
Author(s): Gang Zhou, George Wilson, Jacob George and Liang Qiao
Affiliation:
Keywords: Chemoresistance, differentiation, hepatocellular carcinoma, liver cancer stem cells, micro-RNA, self-renewal, signaling pathways.
Abstract: Cancer stem cells (CSCs) are a subset of cells within tumours that have the ability to selfrenew, differentiate and resist both chemotherapy and radiotherapy. Evidence has emerged in recent years to support liver cancer stem cells (LCSCs) as the key tumour initiating cells and major drivers of tumour progression in hepatocellular carcinoma (HCC). Currently the major approaches to targeting LCSCs are ablating the expression of LCSC markers, disruption of key LCSCs signaling pathways, micro-RNA or siRNA targeting, inducing differentiation of LCSCs and the disruption of chemoresistance of LCSCs. However, complex crosstalk amongst gene regulatory pathways in LCSCs provides a major barrier in implementing these approaches in a clinical setting. Given these findings a deeper understanding of the pathways that mediate LCSC tumourigenesis is imperative for developing new therapeutic strategies for HCC and to improve clinical outcomes.
Export Options
About this article
Cite this article as:
Zhou Gang, Wilson George, George Jacob and Qiao Liang, Targeting Cancer Stem Cells as a Therapeutic Approach in Liver Cancer, Current Gene Therapy 2015; 15 (2) . https://dx.doi.org/10.2174/1566523214666141224095938
DOI https://dx.doi.org/10.2174/1566523214666141224095938 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Cryopreservation of Ovarian Tissue: State of the Art in 2007
Current Women`s Health Reviews Ex Vivo Gene Therapy and Vision
Current Gene Therapy Recent Developments of DNA Poisons - Human DNA Topoisomerase IIα Inhibitors - as Anticancer Agents
Current Pharmaceutical Design Evolutionary Advantage and Molecular Modes of Action of Multi-Component Mixtures Used in Phytomedicine
Current Drug Metabolism Novel Molecular Anti- Colorectalcancer Conjugate:Chlorambucil-Adipic Acid Dihydrizide-Glutamine
Anti-Cancer Agents in Medicinal Chemistry Advances of Phenoxazines: Synthesis, Reactivity and Their Medicinal Applications
Current Medicinal Chemistry Small Activating RNAs as Promising Agents for Biotechnological Use
Current Pharmaceutical Biotechnology Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer
Current Pharmaceutical Biotechnology Pluripotency and Targeted Reprogramming: Strategies, Disease Modeling and Drug Screening
Current Drug Delivery DNA Binding Mode of Transition Metal Complexes, A Relationship to Tumor Cell Toxicity
Current Medicinal Chemistry Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
Current Pharmaceutical Biotechnology Biological Abilities of Rice Bran-Derived Antioxidant Phytochemicals for Medical Therapy
Current Topics in Medicinal Chemistry Role of Monitoring Thiopurine Methyltransferase (TPMT) Activity in the Individualized Therapy with Azathioprine or 6-Mercaptopurine
Current Pharmacogenomics and Personalized Medicine Multi-Nuclear Platinum Drugs: A New Paradigm in Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
Current Cancer Drug Targets Sumoylation in Cellular Senescence and Aging
Current Molecular Medicine Antiplatelet and Antileukocyte Effects of Cardiovascular,Immunomodulatory and Chemotherapeutic Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Drug Delivery Letters The Protein Profile of Fibroblasts: The Role of Proteomics
Current Proteomics